Your browser is no longer supported. Please, upgrade your browser.
Renalytix Plc
Index- P/E- EPS (ttm)-1.04 Insider Own- Shs Outstand36.12M Perf Week-11.96%
Market Cap524.40M Forward P/E- EPS next Y-0.62 Insider Trans- Shs Float32.69M Perf Month-9.49%
Income-37.60M PEG- EPS next Q-0.12 Inst Own17.90% Short Float1.62% Perf Quarter-45.80%
Sales2.00M P/S262.20 EPS this Y-191.50% Inst Trans-0.49% Short Ratio4.66 Perf Half Y-56.67%
Book/sh1.66 P/B8.16 EPS next Y-77.10% ROA-46.70% Target Price28.50 Perf Year-51.71%
Cash/sh- P/C- EPS next 5Y- ROE-50.40% 52W Range12.99 - 35.71 Perf YTD-14.84%
Dividend- P/FCF- EPS past 5Y- ROI-44.10% 52W High-61.47% Beta-
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin45.00% 52W Low5.93% ATR1.21
Employees48 Current Ratio7.80 Sales Q/Q- Oper. Margin- RSI (14)39.44 Volatility8.62% 7.60%
OptionableYes Debt/Eq0.01 EPS Q/Q-35.30% Profit Margin- Rel Volume0.96 Prev Close13.54
ShortableYes LT Debt/Eq0.00 EarningsDec 07 BMO Payout- Avg Volume113.83K Price13.76
Recom2.50 SMA20-9.88% SMA50-17.10% SMA200-43.79% Volume80,392 Change1.62%
Jan-18-22Initiated H.C. Wainwright Buy $30
Jan-04-22Initiated BTIG Research Buy $24
Oct-04-21Initiated Guggenheim Buy $28
Jul-02-21Initiated Berenberg Buy $38
Aug-11-20Initiated Stifel Buy
Jan-20-22 07:47AM  
Jan-11-22 08:15AM  
Jan-10-22 07:00AM  
Jan-07-22 07:00AM  
Jan-05-22 07:00AM  
Jan-04-22 11:17AM  
Dec-02-21 07:00AM  
Nov-20-21 06:09AM  
Nov-10-21 07:00AM  
Nov-09-21 07:00AM  
Oct-25-21 01:53PM  
Oct-21-21 07:00AM  
Oct-08-21 07:00AM  
Oct-07-21 07:00AM  
Sep-29-21 01:14PM  
Sep-14-21 07:00AM  
Sep-09-21 06:03AM  
Sep-03-21 07:00AM  
Aug-30-21 07:00AM  
Aug-26-21 07:00AM  
Aug-03-21 06:16AM  
Jul-28-21 07:00AM  
Jul-26-21 07:00AM  
Jul-22-21 07:00AM  
Jul-16-21 06:19AM  
Jul-11-21 08:43AM  
Jun-28-21 07:00AM  
Jun-15-21 07:00AM  
Jun-10-21 08:00AM  
Jun-07-21 07:00AM  
Jun-03-21 07:00AM  
Jun-02-21 11:34AM  
May-19-21 07:00AM  
May-04-21 02:20PM  
Apr-22-21 07:00AM  
Apr-20-21 07:21AM  
Apr-14-21 07:00AM  
Apr-08-21 07:00AM  
Apr-05-21 07:00AM  
Mar-15-21 07:00AM  
Mar-10-21 10:31AM  
Mar-04-21 01:00PM  
Mar-02-21 07:00AM  
Feb-24-21 08:00AM  
Feb-23-21 02:00AM  
Feb-10-21 11:31AM  
Feb-08-21 07:30AM  
Feb-04-21 07:00AM  
Jan-13-21 02:00AM  
Jan-06-21 08:54AM  
Jan-05-21 06:00AM  
Jan-04-21 08:05AM  
Nov-29-20 11:42AM  
Nov-25-20 07:30AM  
Nov-13-20 02:00AM  
Nov-06-20 07:00AM  
Nov-02-20 10:30AM  
Oct-28-20 07:30AM  
Oct-27-20 03:00AM  
Oct-26-20 07:30AM  
Sep-22-20 07:00AM  
Sep-18-20 07:00AM  
Aug-26-20 07:00AM  
Aug-21-20 03:00AM  
Aug-03-20 08:00AM  
Jul-27-20 08:00AM  
Jul-21-20 03:57PM  
Jul-16-20 11:38PM  
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.